Answers are grounded in this paper and cite their sources.
Many pharmaceutical companies, especially biotechnology companies, are now commercializing innovative so-called expensive medicinal products, e.g. biologicals, and especially orphan drugs, with an incremental cost-effectiveness ratio (ICER), which will probably exceed threshold values that are commonly regarded as acceptable for reimbursement
No takes yet. Share an insight, caveat, or question.
Mark Nuijten (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: